[go: up one dir, main page]

MX2020005478A - Compuestos de sulfonamida y usos de los mismos. - Google Patents

Compuestos de sulfonamida y usos de los mismos.

Info

Publication number
MX2020005478A
MX2020005478A MX2020005478A MX2020005478A MX2020005478A MX 2020005478 A MX2020005478 A MX 2020005478A MX 2020005478 A MX2020005478 A MX 2020005478A MX 2020005478 A MX2020005478 A MX 2020005478A MX 2020005478 A MX2020005478 A MX 2020005478A
Authority
MX
Mexico
Prior art keywords
sulfonamide compounds
compounds
sulfonamide
preparing
present disclosure
Prior art date
Application number
MX2020005478A
Other languages
English (en)
Inventor
Hiroyuki Nakamura
Jing Teng
Nathan Gignac
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2020005478A publication Critical patent/MX2020005478A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente descripción se refiere a nuevas formas cristalinas de compuestos de sulfonamida, composiciones farmacéuticas que contienen los compuestos de forma cristalina y métodos de preparación y uso de los mismos.
MX2020005478A 2017-11-29 2018-11-28 Compuestos de sulfonamida y usos de los mismos. MX2020005478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592023P 2017-11-29 2017-11-29
PCT/IB2018/059430 WO2019106579A1 (en) 2017-11-29 2018-11-28 Sulfonamide compounds and use thereof

Publications (1)

Publication Number Publication Date
MX2020005478A true MX2020005478A (es) 2020-08-27

Family

ID=66665441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005478A MX2020005478A (es) 2017-11-29 2018-11-28 Compuestos de sulfonamida y usos de los mismos.

Country Status (16)

Country Link
US (2) US12344588B2 (es)
EP (1) EP3717462B1 (es)
JP (1) JP6846574B2 (es)
KR (1) KR102480074B1 (es)
CN (1) CN111386260B (es)
AU (1) AU2018377036B2 (es)
BR (1) BR112020010148A2 (es)
CA (1) CA3084030C (es)
ES (1) ES2969901T3 (es)
MA (1) MA51224A (es)
MX (1) MX2020005478A (es)
MY (1) MY201832A (es)
PH (1) PH12020550703A1 (es)
SG (1) SG11202004877UA (es)
TW (1) TWI762743B (es)
WO (1) WO2019106579A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563057B (zh) 2016-05-31 2022-06-24 大鹏药品工业株式会社 磺酰胺化合物或其盐
WO2018187479A1 (en) 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase
MX2020005478A (es) 2017-11-29 2020-08-27 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida y usos de los mismos.
WO2022187200A1 (en) * 2021-03-02 2022-09-09 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof
JP2024534421A (ja) * 2021-09-17 2024-09-20 バウンドレス バイオ，インク． スルファミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用
AU2022345092A1 (en) * 2021-09-17 2024-04-04 Boundless Bio, Inc. Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
JP2025531147A (ja) * 2022-09-13 2025-09-19 バウンドレス バイオ，インク． 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO1999039732A1 (en) * 1998-02-09 1999-08-12 Aventis Pharmaceuticals Products Inc. Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections
AU1182300A (en) * 1998-11-17 2000-06-05 Fuji Photo Film Co., Ltd. Bisaryl compounds and cancer remedies containing the same
AU6894400A (en) * 1999-08-06 2001-03-05 Enzon Pharmaceuticals Inc. Composition and methods for treatment of HIV infection
US20020028828A1 (en) 2000-05-02 2002-03-07 Chung-Chen Wei (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
JP2004507548A (ja) 2000-08-31 2004-03-11 ドクター・レディーズ・ラボラトリーズ・リミテッド オランザピン水和物の調製方法、及びこれを結晶形態のオランザピンに変換する方法
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
WO2004014300A2 (en) 2002-08-09 2004-02-19 Merck & Co., Inc. Tyrosine kinase inhibitors
RU2383536C2 (ru) 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
MY142304A (en) * 2005-01-31 2010-11-15 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound or salt thereof
TW200736234A (en) * 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
CN101415691B (zh) * 2006-02-03 2011-12-14 大正制药株式会社 三唑衍生物
CN101820757A (zh) 2007-06-01 2010-09-01 普林斯顿大学托管委员会 通过调节宿主细胞代谢途径治疗病毒感染
KR20110086142A (ko) 2008-11-11 2011-07-27 노파르티스 아게 핑골리모드의 염
AU2015203322B2 (en) 2009-07-20 2016-09-29 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2011121453A2 (en) 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
GB201420239D0 (en) 2014-11-14 2014-12-31 Bergenbio As Biomarker
TWI623316B (zh) 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
CN109563057B (zh) 2016-05-31 2022-06-24 大鹏药品工业株式会社 磺酰胺化合物或其盐
US10889555B2 (en) * 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
MX2020005478A (es) 2017-11-29 2020-08-27 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida y usos de los mismos.
WO2019107386A1 (ja) 2017-11-29 2019-06-06 大鵬薬品工業株式会社 抗腫瘍剤
MX2020011332A (es) 2018-04-25 2021-04-13 Anna Martner Metodos y composiciones para reducir el riesgo de recaida y prolongar la supervivencia en leucemia mieloide aguda.

Also Published As

Publication number Publication date
CN111386260A (zh) 2020-07-07
CN111386260B (zh) 2024-04-30
US12344588B2 (en) 2025-07-01
US20200361883A1 (en) 2020-11-19
CA3084030A1 (en) 2019-06-06
ES2969901T3 (es) 2024-05-23
SG11202004877UA (en) 2020-06-29
JP6846574B2 (ja) 2021-03-24
KR20200096261A (ko) 2020-08-11
EP3717462A4 (en) 2021-07-21
JP2021504432A (ja) 2021-02-15
TWI762743B (zh) 2022-05-01
US20250223270A1 (en) 2025-07-10
RU2020121153A (ru) 2021-12-29
AU2018377036B2 (en) 2022-04-14
PH12020550703A1 (en) 2021-04-26
WO2019106579A1 (en) 2019-06-06
EP3717462B1 (en) 2024-01-03
CA3084030C (en) 2023-03-21
MA51224A (fr) 2020-10-07
MY201832A (en) 2024-03-19
TW201925182A (zh) 2019-07-01
BR112020010148A2 (pt) 2020-10-13
RU2020121153A3 (es) 2021-12-29
AU2018377036A1 (en) 2020-06-18
EP3717462A1 (en) 2020-10-07
KR102480074B1 (ko) 2022-12-21

Similar Documents

Publication Publication Date Title
PH12020550703A1 (en) Sulfonamide compounds and use thereof
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
PH12017502255B1 (en) Nrf2 regulators
MX378732B (es) Formas solidas novedosas
MX364069B (es) Moduladores de la proteína activadora de 5-lipoxigenasa.
TW201613864A (en) Novel compounds
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
EA201790570A1 (ru) Модуляторы р2х7
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
GEP20186893B (en) Pyrazines modulators of gpr6
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
WO2019006292A8 (en) Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation